Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae319 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Kieren J Mather und 11 weiteren Autor:innen. Beteiligte Einrichtung: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Insulin Resistance. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Context
In a clinical study, tirzepatide, a glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist (GIP/GLP-1RA), provided superior glycemic control vs the GLP-1RA semaglutide. The physiologic mechanisms are incompletely understood.
Objective
This work aimed to evaluate treatment effects by model-based analyses of mixed-meal tolerance test (MMTT) data.
Methods
A 28-week double–blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany. Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo. Main outcome measures included glycemic control, model-derived β-cell function indices including insulin secretion rate (ISR) at 7.2–mmol/L glucose (ISR7.2), β-cell glucose sensitivity (β-CGS), insulin sensitivity, and estimated hepatic insulin-to-glucagon ratio.
Results
Tirzepatide significantly reduced fasting glucose and MMTT total glucose area under the curve (AUC) vs semaglutide (P < .01). Incremental glucose AUC did not differ significantly between treatments; therefore, greater total glucose AUC reduction with tirzepatide was mainly attributable to greater suppression of fasting glucose. A greater reduction in total ISR AUC was achieved with tirzepatide vs semaglutide (P < .01), in the context of greater improvement in insulin sensitivity with tirzepatide (P < .01). ISR7.2 was significantly increased with tirzepatide vs semaglutide (P < .05), showing improved β-CGS. MMTT-derived β-CGS was increased but not significantly different between treatments. Both treatments reduced fasting glucagon and total glucagon AUC, with glucagon AUC significantly reduced with tirzepatide vs semaglutide (P < .01). The estimated hepatic insulin-to-glucagon ratio did not change substantially with either treatment.
Conclusion
These results suggest that the greater glycemic control observed for tirzepatide manifests as improved fasting glucose and glucose excursion control, due to improvements in ISR, insulin sensitivity, and glucagon suppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
- Institute of Neuroscience, National Research Council, 2-35122 Padua, Italy.
- Profil Institute for Metabolic Research, 41460 Neuss, Germany.
ORCID-Profile: Kieren J Mather, Andrea Mari, J Hans DeVries, Melissa K Thomas
Zitieren
APA
Mather, K. J., Mari, A., Heise, T., DeVries, J. H., Hua, M., Urva, S., Coskun, T., Haupt, A., Heine, R. J., Pratt, E., Thomas, M. K., & Milicevic, Z. (2024). Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae319
Vancouver
Mather KJ, Mari A, Heise T, DeVries JH, Hua M, Urva S, et al. Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae319
BibTeX
@article{Mather2024,
author = {Mather, Kieren J and Mari, Andrea and Heise, Tim and DeVries, J Hans and Hua, Ming and Urva, Shweta and Coskun, Tamer and Haupt, Axel and Heine, Robert J and Pratt, Edward and Thomas, Melissa K and Milicevic, Zvonko},
title = {Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae319}
}
EUVIMED